Press Releases Items Per Page 102550 Year None202320222021202020192018201720162015201420132012201120102007 12.06.22 Syndax Announces Proposed $150 million Public Offering of Common Stock 12.05.22 Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia 12.05.22 Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology 12.02.22 Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer 11.21.22 Syndax Announces Participation at Evercore ISI Annual HealthCONx Conference 11.03.22 Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update 11.03.22 Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias 10.27.22 Syndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022 08.08.22 Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update 08.02.22 Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022 06.13.22 Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer 05.26.22 Syndax Announces Participation at Two Upcoming Investor Conferences Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
12.05.22 Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia
12.05.22 Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
11.03.22 Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
11.03.22 Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias
10.27.22 Syndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022
08.08.22 Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
08.02.22 Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022
